<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Little is known about the rate of progression or associations of <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> in <z:hpo ids='HP_0000726'>dementia</z:hpo> with <z:hpo ids='HP_0100315'>Lewy bodies</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>), or the associations of accelerated decline </plain></SENT>
<SENT sid="1" pm="."><plain>METHOD: <z:hpo ids='HP_0000726'>Dementia</z:hpo> patients from a case register were evaluated at baseline and 1 year follow-up using the Cambridge Assessment for <z:e sem="disease" ids="C0004936" disease_type="Mental or Behavioral Dysfunction" abbrv="">Mental Disorders</z:e> in the Elderly, section B (CAMCOG) and the Mini-Mental State Examination (MMSE) to determine the rate of <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Operationalized clinical diagnoses were applied (NINCDS ADRDA for <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD), NINCDS AIRENS for vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD) and consensus criteria for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: One hundred and ninety-three patients completed annual MMSE schedules (AD, 101; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>, 64; VaD, 38), of whom 154 completed the CAMCOG </plain></SENT>
<SENT sid="4" pm="."><plain>The magnitude of <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> (MMSE, 4-5 points; CAMCOG, 12-14 points) was similar in each of the <z:hpo ids='HP_0000726'>dementias</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The strongest predictor of accelerated <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e> was the <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> E4 allele (17.5 vs 8.3 points decline on the CAMCOG) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Over 1 year, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>, VaD and AD patients had similar rates of <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> overall </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="39015">Apolipoprotein</z:chebi> E4 may be an important predictor of more rapid decline in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e> </plain></SENT>
</text></document>